Methods and compositions for inhibition of vascular permeability

1. A method of inhibiting vascular permeability in a subject having a vascular permeability associated disease or disorder comprising administering to said subject a pharmaceutical composition comprising an effective amount of a peptide selected from the group consisting of SEQ ID NOs: 1, 2 or 4, and a pharmaceutically-acceptable carrier, wherein said peptide inhibits the p21-activated kinase (PAK)-PIX-GIT interaction or complex formation.

2. The method of claim 1 , wherein said peptide inhibits an increase in vascular permeability.

3. The method of claim 2 , wherein said peptide inhibits a growth factor-stimulated increase in vascular permeability.

4. The method of claim 2 , wherein said peptide inhibits a cytokine-stimulated increase in vascular permeability.

5. The method of claim 2 , wherein said peptide inhibits a bacterial toxin-stimulated increase in vascular permeability.

6. The method of claim 1 , wherein said peptide comprises an amino acid sequence to enhance cell membrane permeability.

7. The method of claim 1 , wherein said peptide inhibits the PAK-PIX-GIT interaction or complex formation by inhibiting the interaction or complex formation of PAK-PIX or PIX GIT.

8. The method of claim 7 , wherein PIX is PIXα or PIXβ.

9. The method of claim 7 , wherein GIT is GIT1 or GIT2.

10. The method of claim 1 , wherein said peptide inhibits Erk activation.

11. The method of claim 1 , wherein said peptide inhibits MLCK activation.

12. The method of claim 1 , wherein said subject has a vascular permeability-associated disease or disorder selected from the group consisting of tissue damage, ischemia, inflammation, stroke, wound healing, acute respiratory distress syndrome, hypertension, myocardial infarction, sepsis, hypoxia, infection, allergic reaction, thermal injury, x-irradiation, and ultraviolet irradiation.

13. The method of claim 1 , wherein said vascular permeability-associated disease or disorder is lung inflammation.